HONG
KONG, July 6, 2022 /PRNewswire/ -- Global
Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing and stem cell storage services, today announced that an
injunction order (the "Order") previously obtained by the Company
on June 15, 2022 from the Grand Court
of the Cayman Islands (the
"Court") against Blue Ocean Structure Investment Company Limited
("Blue Ocean") was officially issued by the Court on July 6, 2022. The Order provides, among other
things, that:
Until further order of the Court, any resolution or resolutions
("Resolutions") that might be passed or purported to be passed at
any extraordinary general meeting of the Company to be held or
purporting to be held on June 16,
2022 ("the Purported EGM") or other meeting held or
purporting to be held pursuant to a Notice of Extraordinary General
Meeting dated June 3, 2022 (on
June 16, 2022 or any other date)
shall not take effect and shall not be implemented, and Blue Ocean
must not:
- rely or purport to rely upon any such Resolutions; and/or
- seek to convene or convene any extraordinary general meeting of
the Company or other meeting.
There will be a further hearing in respect of the Order and
other matters on July 13-15, 2022.
The Company cautions its shareholders and others considering
trading its ordinary shares to remain alert to the risks related to
the present proceedings. The Company looks forward to providing
investors with an update as and when it is appropriate to do
so.
About Global Cord Blood Corporation
Global Cord Blood Corporation is an umbilical cord blood banking
operator serving multiple regions in China. Global Cord Blood Corporation provides
cord blood collection, laboratory testing, hematopoietic stem cell
processing and stem cell storage services. For more information,
please visit the Company's website at:
http://www.globalcordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These
statements relate to future events or the Company's future
financial performance. The Company has attempted to identify
forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates",
"intends", "may", "plans", "potential", "predict", "should" or
"will" or the negative of these terms or other comparable
terminology. These statements are only predictions, uncertainties
and other factors may cause the Company's actual results, levels of
activity, performance or achievements to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking
statements. The information in this press release is not intended
to project future performance of the Company. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company does not guarantee future
results, levels of activity, performance or achievements. The
Company expectations are as of the date this press release is
issued, and the Company does not intend to update any of the
forward-looking statements after the date this press release is
issued to conform these statements to actual results, unless
required by law.
View original
content:https://www.prnewswire.com/news-releases/global-cord-blood-corporation-obtained-injunction-order-against-blue-ocean-in-respect-of-purported-egm-301581767.html
SOURCE Global Cord Blood Corporation